|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's range||11.10 - 12.42|
|52-week range||2.66 - 39.00|
|Beta (5Y monthly)||2.53|
|PE ratio (TTM)||N/A|
|Earnings date||01 Nov 2023 - 06 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||17.75|
Aeglea's (AGLE) shares surge as it acquires Spyre Therapeutics, a private company that focuses on developing antibody therapeutics for inflammatory bowel disease.
A reverse acquisition in biopharma, litigation over a cancer drug ends for GSK and Ocado takeover rumours are moving markets.
Aeglea (AGLE) delivered earnings and revenue surprises of -5.26% and 16.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?